🇺🇸 FDA
Patent

US 8568739

Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses

granted A61KA61K2039/5254A61K2039/5256

Quick answer

US patent 8568739 (Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/5254, A61K2039/5256, A61K2039/70, A61K39/12